Immune Design Corp. (NASDAQ:IMDZ) – Investment analysts at Leerink Swann boosted their Q3 2017 earnings estimates for shares of Immune Design Corp. in a research note issued to investors on Thursday. Leerink Swann analyst S. Fernandez now anticipates that the biotechnology company will post earnings per share of ($0.67) for the quarter, up from their previous forecast of ($0.68). Leerink Swann also issued estimates for Immune Design Corp.’s FY2017 earnings at ($2.40) EPS, FY2018 earnings at ($2.21) EPS, FY2019 earnings at ($2.50) EPS, FY2020 earnings at ($2.42) EPS and FY2021 earnings at ($1.89) EPS.

Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. The business had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.50 million.

WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/07/leerink-swann-weighs-in-on-immune-design-corp-s-q3-2017-earnings-nasdaqimdz.html.

Several other equities research analysts also recently commented on the company. Jefferies Group LLC reiterated a “buy” rating and set a $18.00 target price (up from $16.00) on shares of Immune Design Corp. in a report on Friday, May 19th. Zacks Investment Research upgraded Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Thursday, May 18th. Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a report on Tuesday, June 6th. ValuEngine upgraded Immune Design Corp. from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, BidaskClub downgraded Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Immune Design Corp. has an average rating of “Buy” and an average target price of $14.50.

Immune Design Corp. (NASDAQ:IMDZ) opened at 10.475 on Monday. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $13.05. The stock’s 50 day moving average price is $9.47 and its 200-day moving average price is $7.03. The firm’s market capitalization is $268.36 million.

In related news, Director Lewis W. Coleman bought 8,000 shares of the company’s stock in a transaction that occurred on Friday, July 7th. The shares were acquired at an average cost of $9.27 per share, for a total transaction of $74,160.00. Following the acquisition, the director now owns 40,000 shares in the company, valued at approximately $370,800. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Lewis W. Coleman bought 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 11th. The shares were bought at an average price of $9.05 per share, for a total transaction of $108,600.00. Following the completion of the acquisition, the director now owns 40,000 shares in the company, valued at approximately $362,000. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 30,000 shares of company stock worth $272,760. Company insiders own 42.90% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Victory Capital Management Inc. increased its stake in shares of Immune Design Corp. by 11.6% in the first quarter. Victory Capital Management Inc. now owns 1,937,554 shares of the biotechnology company’s stock valued at $13,175,000 after buying an additional 202,149 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Immune Design Corp. by 170.0% in the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock valued at $760,000 after buying an additional 70,351 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Immune Design Corp. by 46.5% in the first quarter. Wells Fargo & Company MN now owns 148,887 shares of the biotechnology company’s stock valued at $1,012,000 after buying an additional 47,266 shares during the last quarter. Personal Capital Advisors Corp bought a new stake in shares of Immune Design Corp. during the second quarter valued at approximately $356,000. Finally, Trexquant Investment LP bought a new stake in shares of Immune Design Corp. during the first quarter valued at approximately $183,000. Institutional investors and hedge funds own 50.60% of the company’s stock.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.